Pharnext is an advanced clinical-stage biopharmaceutical developing novel therapeutics targeting severe neurodegenerative diseases - rare or common - that currently lack curative and/or disease modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase 3 trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A (orphan drug status). PXT864 has generated encouraging Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm: PLEOTHERAPY™.
First Time Exhibitor No